Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.76 |
| ▸ | RET | P07949 | 11/20 | 0.71 |
| ▸ | KDR | P35968 | 6/20 | 0.71 |
| ▸ | FLT1 | P17948 | 1/20 | 0.71 |
| ▸ | KIF5B | P33176 | 6/20 | 0.68 |
| ▸ | LCK | P06239 | 1/20 | 0.64 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6180124 | 0.99 | EGFR (0.74) | EGFRRETKDRFLT1KIF5B | |
| SCHEMBL8976474 | 0.87 | EGFR (0.66) | EGFRRETKDRFLT1KIF5B | |
| SCHEMBL8976518 | 0.87 | EGFR (0.76) | EGFRRETKDRFLT1KIF5B | |
| SCHEMBL8976490 | 0.85 | RET (0.65) | EGFRRETKDRFLT1KIF5B | |
| SCHEMBL8976704 | 0.85 | EGFR (1.00) | EGFRRETKDRFLT1LCK | |
| SCHEMBL12200787 | 0.84 | RET (0.74) | EGFRRETKDRFLT1KIF5B | |
| SCHEMBL8976335 | 0.84 | RET (0.65) | EGFRRETKDRFLT1KIF5B | |
| SCHEMBL7116324 | 0.83 | SRC (0.75) | EGFRRETKDRFLT1KIF5B | |
| SCHEMBL5864529 | 0.83 | KDR (1.00) | EGFRRETKDRFLT1KIF5B | |
| SCHEMBL7116313 | 0.83 | RET (0.73) | EGFRRETKDRFLT1KIF5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0871448-B1 | ARYL AND HETEROARYL QUINAZOLINE COMPOUNDS WHICH INHIBIT CSF-1R RECEPTOR TYROSINE KINASE | AVENTIS PHARMA INC (US) | 2005-03-02 | — | — | EP | claimed |
| CN-1100540-C | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties | AVENTIS PHARMA INC (US) | 2003-02-05 | — | — | CN | claimed |
| US-RE37650-E1 | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase | AVENTIS PHARMACETICAL PRODUCTS, INC. | 2002-04-09 | — | — | US | claimed |
| CN-1187129-A | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties | RHONE POULENC RORER PHARMA (US) | 1998-07-08 | — | — | CN | claimed |
| EP-0831831-A4 | PROTEIN TYROSINE KINASE ARYL AND HETEROARYL QUINAZOLINE COMPOUNDS HAVING SELECTIVE INHIBITION OF HER-2 AUTOPHOSPHORYLATION PROPERTIES | RHONE POULENC RORER PHARMA (US) | 1998-05-27 | — | — | EP | claimed |
| EP-0831831-A1 | PROTEIN TYROSINE KINASE ARYL AND HETEROARYL QUINAZOLINE COMPOUNDS HAVING SELECTIVE INHIBITION OF HER-2 AUTOPHOSPHORYLATION PROPERTIES | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1998-04-01 | — | — | EP | claimed |
| US-5721237-A | ADMINISTERING FOR THE SELECTIVE TREATMENT OF CELL GROWTH AND DIFFERENTIATION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-02-24 | — | — | US | claimed |
| US-5710158-A | INHIBITORS OF PROTEIN TYROSINE KINASE AND EPIDERMAL GROWTH FACTOR | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-01-20 | — | — | US | claimed |
| WO-1996039145-A1 | PROTEIN TYROSINE KINASE ARYL AND HETEROARYL QUINAZOLINE COMPOUNDS HAVING SELECTIVE INHIBITION OF HER-2 AUTOPHOSPHORYLATION PROPERTIES | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-12-12 | — | — | WO | claimed |
| CN-1100540-C | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties | AVENTIS PHARMA INC (US) | 2003-02-05 | — | — | CN | disclosed |
| US-6057320-A | ANTIPROLIFERATIVE AGENTS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-05-02 | — | — | US | disclosed |
| US-RE36256-E | ADMINISTERING ARYL-SUBSTITUTED QUINOXALINE DERIVATIVES AS ANTIPROLIFERATIVE, ANTICARCINOGENIC AND ANTITUMOR AGENTS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-07-20 | — | — | US | disclosed |
| US-5795889-A | INHIBITING CELL GROWTH WITH ENZYME INHIBITORS FOR SKIN DISORDERS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-08-18 | — | — | US | disclosed |
| CN-1187129-A | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties | RHONE POULENC RORER PHARMA (US) | 1998-07-08 | — | — | CN | disclosed |
| US-5646153-A | INHIBITING ABNORMAL CELL PROLIFERATION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-08 | — | — | US | disclosed |
| US-5480883-A | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-01-02 | — | — | US | disclosed |